Andecaliximab

Andecaliximab 是一种靶向基质金属蛋白酶 9 (MMP9) 的重组 IgG4 单克隆抗体。Andecaliximab 在特发性肺纤维化小鼠模型中显示出抗纤维化作用。Andecaliximab 可用于研究胃腺癌和特发性肺纤维化 (IPF) 以及登革热病毒。

CAS号

1518996-49-0

分子式

主要靶点

Virus Protease|MMP

仅限科研使用

Cat No : CM20820

Print datasheet

Synonyms

GS-5745



产品信息

Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used to study gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF), as well as dengue virus.

CAS号 1518996-49-0
分子式
主要靶点 Virus Protease|MMP
主要通路 蛋白酶体|微生物学
分子量
纯度 , 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件
别名 GS-5745

体内活性

Improving the diversity of T cell receptor (TCR) in tumor-infiltrating T cells, andecaliximab[1]. In a human NSG mouse model of idiopathic pulmonary fibrosis, andecaliximab (20 mg/kg; intraperitoneal injection, single) exhibited an anti-fibrosis effect[2].

体外活性

Andecaliximab increases serum IL-7 levels [ 1 ]. Andecaliximab ( 50 μg / mL ; 24 h ) reduced the phosphorylation of SMAD2 ( pSMAD2 ) in ABC cell lines [ 2 ].

参考文献

1.Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
2.Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2